Fortrea Holdings Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$10.30
+$0.21 (+2.08%) 1:15 PM ET
Prev closePrevC$10.09
OpenOpen$10.43
Day highHigh$10.52
Day lowLow$10.16
VolumeVol307,890
Avg volAvgVol1,293,160
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$943.42M
P/E ratio
-0.95
FY Revenue
$2.72B
EPS
-10.84
Gross Margin
18.50%
Sector
Healthcare
AI report sections
MIXED
FTRE
Fortrea Holdings Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−7% (Below avg)
Vol/Avg: 0.93×
RSI
53.69(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
-0.01 (Weak)
MACD: -0.00 Signal: 0.01
Short-Term
+0.19 (Strong)
MACD: -0.19 Signal: -0.38
Long-Term
+0.21 (Strong)
MACD: -1.15 Signal: -1.37
Intraday trend score
46.30
LOW46.30HIGH54.30
Latest news
FTRE•12 articles•Positive: 4Neutral: 5Negative: 3
PositiveGlobeNewswire Inc.• Fortrea
Fortrea dévoile Fortrea Intelligent Technology™ : une technologie destinée à permettre aux investigateurs et aux centres d’essais cliniques de mener des essais plus intelligents et mieux intégrés
Fortrea, a leading global contract research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered suite of solutions designed to revolutionize clinical trial processes. FIT automates workflows, streamlines oversight, and improves productivity for investigators, clinical trial centers, and research teams. The platform builds on Fortrea's flagship Xcellerate® platform and incorporates AI and machine learning to analyze complex patterns, generate predictive signals, and reduce manual tasks while enabling faster decision-making and risk management.
Fortrea announced a significant product innovation (FIT) that enhances its core offerings with AI-powered solutions. The launch demonstrates technological advancement, expanded capabilities across clinical trial processes, and positions the company competitively in the CRO market. Executive quotes emphasize transformative potential and improved efficiency for clients, indicating strong confidence in the new platform.
Fortrea, a leading global clinical research organization, launched Fortrea Intelligent Technology (FIT), an AI-driven solution suite designed to transform clinical trial operations. FIT automates workflows, streamlines oversight, and provides real-time insights to sponsors, research sites, and study teams. Built on the Xcellerate® platform, the solution features three pillars: full lifecycle management, foresight analytics, and AI-powered companion tools to accelerate trial delivery and improve quality.
FTREclinical trialsAI-powered solutionsworkflow automationXcellerate platformrisk-based quality managementclinical developmentdrug development
Sentiment note
Fortrea announced a significant product innovation (FIT) that enhances its core platform capabilities with AI and machine learning. The solution addresses key pain points in clinical trial operations, positions the company as a technology leader in the CRO space, and is expected to drive competitive advantage and customer value. Leadership quotes emphasize transformational impact and responsible AI implementation.
Fortrea, a leading global clinical research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered solution designed to automate workflows and streamline clinical trial operations. Built on the Xcellerate® platform, FIT offers three pillars: full lifecycle trial management, data-driven foresight analytics, and AI-powered companion tools to improve trial speed, predictability, and quality for sponsors and research sites.
FTREclinical trialsartificial intelligenceworkflow automationXcellerate platformclinical research organizationrisk-based quality managementdrug development
Sentiment note
Fortrea announced a significant innovation with FIT, an AI-powered platform designed to improve clinical trial operations. The solution addresses key pain points in drug development by automating workflows, enhancing decision-making through data analytics, and improving trial efficiency. Leadership quotes emphasize revolutionary transformation and faster delivery of life-changing therapies, indicating strong confidence in the product's market impact and competitive positioning.
NegativeGlobeNewswire Inc.• Grabar Law Office
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Grabar Law Office is investigating potential securities fraud and fiduciary breaches for several publicly traded companies, alleging misleading statements and undisclosed business risks that potentially harmed shareholders.
Allegations of overstating revenue projections, cost savings, and business prospects following Labcorp spinoff
NeutralGlobeNewswire Inc.• Fortrea
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea announced granting 245,000 restricted stock units (RSUs) to two newly hired employees, with vesting occurring in three equal annual installments starting December 10, 2026.
The announcement is a standard corporate action of granting RSUs to new employees, indicating normal business operations without significant positive or negative implications
NegativeGlobeNewswire Inc.• Joshua H. Grabar
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.
Allegations of overstating revenue projections, cost savings, and business prospects post-spin-off
PositiveGlobeNewswire Inc.• Fortrea
Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
Fortrea has completed a debt tender offer, purchasing $75.7 million of its outstanding 7.500% Senior Secured Notes due 2030, reducing the principal outstanding from $570 million to $494.3 million.
The company successfully reduced its debt, reinforced its balance sheet strength, and demonstrated disciplined financial management by using cash on hand to fund the tender offer
NegativeGlobeNewswire Inc.• Grabar Law Office
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); enCore Energy Corp. (NASDAQ: EU); Fortrea Holdings, Inc. (NASDAQ: FTRE); and Stride, Inc. (NYSE: LRN): Grabar Law Office Investigates Claims on Your Behalf
Law firm Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for four publicly traded companies, alleging misleading statements and undisclosed material facts that impacted investor interests.
Claims of overestimating revenue, overstating cost savings, and inflating EBITDA targets
NeutralGlobeNewswire Inc.• Tracy Krumme
Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call
Fortrea, a global contract research organization, will release its third quarter 2025 financial results on November 5, 2025, with a conference call scheduled at 8:00 am ET to review the results and conduct a Q&A session.
FTREfinancial resultsearnings callcontract research organizationclinical development
Sentiment note
The article is a standard financial results announcement without indicating positive or negative performance, presenting routine corporate communication about an upcoming earnings call
NeutralGlobeNewswire Inc.• Fortrea
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea announced granting 75,000 restricted stock units (RSUs) to a newly hired employee, with vesting occurring in three equal annual installments starting September 12, 2026.
FTRERSUsinducement awardstock grantnew employee
Sentiment note
The announcement is a standard corporate action of granting stock units to a new employee, which does not inherently suggest positive or negative market implications
NeutralThe Motley Fool• Jesterai
Fortrea (FTRE) Q2 Revenue Jumps 7%
Fortrea Holdings reported Q2 2025 revenue of $710.3 million, beating analyst estimates by 12.5%. Despite positive revenue growth and improved adjusted earnings, the company faced challenges including a significant goodwill impairment and a book-to-bill ratio below target.
Mixed financial performance with revenue growth and improved adjusted earnings, offset by goodwill impairment, reduced cash reserves, and below-target book-to-bill ratio
NeutralGlobeNewswire Inc.• Fortrea Holdings Inc.
Fortrea Reports Second Quarter 2025 Results
Fortrea reported Q2 2025 revenues of $710.3 million, with a GAAP net loss of $374.9 million, primarily due to a non-cash goodwill impairment charge. The company raised its 2025 revenue guidance and welcomed new CEO Anshul Thakral.
FTREcontract research organizationclinical developmentfinancial resultsgoodwill impairmentCEO transition
Sentiment note
Mixed financial performance with revenue growth and raised guidance, offset by significant goodwill impairment and net loss, indicating ongoing business challenges and restructuring
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal